1887

Journal of General Virology header logo

Volume 75, Issue 9

Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific Free

Abstract

Forty-two women attending a colposcopy clinic for evaluation of abnormal cervical cytology and 13 normal controls were studied for the presence of lymphocyte proliferation (LP) cell-mediated immune (CMI) responses and serological reactivity to E7 peptides of human papillomavirus type 16 (HPV-16). HPV was typed by Southern blot hybridization of exfoliated cervicovaginal cell DNA. Positive LP responses (stimulation index ⩾ 5·0) to one or more E7 peptides were observed in 28·6% (12 of 42) of patients and 23·1 % (three of 13) of controls. Of patients infected with HPV-16,-31 or -33, 63·6% (seven of 11) showed a positive LP response compared with 14-3 % (two of 14) of women infected with other HPV types ( = 0·02), 17·6 % (three of 17) negative for HPV ( = 0·02) and 23·1 % (three of 13) of controls (HPV status unknown) ( = 0·05). C-terminal peptide 109 (amino acids 72 to 97) elicited positive LP responses in 45-4% (five of 11) of patients infected with HPV -16, -31 or -33 compared with 71 % (one of 14) patients infected with other HPVs ( 0·04), 5·9 % (one of 17) of women negative for HPV ( = 0·02) and 7·7% (one of 13) of controls ( = 0·05). HPV-16 group-specific LP responses of borderline significance were also observed against E7 peptides 103,105 and 108 (17−37, 37−54 and 62−80) ( = 0·07). ELISA reactivity (IgG) to E7 peptide 109 (72−97) was present in 7·7% (one of 13) of controls, 35·3 % (six of 17) of HPV-negative patients, 42·9 % (six of 14) of patients infected with other HPVs, and only 9·1 % (one of 11) of patients infected with HPV-16, -31 or -33. CMI responses to C-terminal HPV-16 E7 peptide 109 (72−97) were thus significantly related to ongoing cervical infection with HPV-16 and closely related types, whereas serological reactivity to E7 peptides was not HPV type-specific.

  • Received:
  • Accepted:
  • Published Online:
© The Journal of General Virology 1994
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-75-9-2277
1994-09-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/75/9/JV0750092277.html?itemId=/content/journal/jgv/10.1099/0022-1317-75-9-2277&mimeType=html&fmt=ahah

References

  1. Altmann A., Jochmus-Kudielka I., Frank R., Gausepohl H., Moebius H., Gissmann L., Meuer S. C. 1992; Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7. European Journal of Cancer 28:326–333
     [Google Scholar]
  2. Beiss B. K., Burk R. D., Heimer E., Felix A. M., Ritter D. B., Kadish A. S. 1991; Type-specific and cross-reactive epitopes in human papillomavirus type 16 capsid proteins: identification using peptide antibodies. Virology 184:460–464
     [Google Scholar]
  3. Burk R. D., Kadish A. S., Calderin S., Romney S. L. 1986; Human papillomavirus infection of the cervix detected by cervico-vaginal lavage and molecular hybridization: correlation with biopsy results and Papanicolaou smear. American Journal of Obstetrics and Gynecology 154:982–989
     [Google Scholar]
  4. Chen L., Thomas E. K., Hu S. L., Hellstrom I., Hellstrom K. E. 1991; Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proceedings of the National Academy of Sciences U.S.A: 88110–114
     [Google Scholar]
  5. Chen L., Mizuno M. T., Singhal M. C., Hu S. -L., Galloway D. A., Hellstrom I., Hellstrom K. E. 1992; Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. Journal of Immunology 148:2617–2621
     [Google Scholar]
  6. Comerford S. A., Mccance D. J., Dougan G., Tite J. P. 1991; Identification of T- and B-cell epitopes of the E7 protein of human papillomavirus type 16. Journal of Virology 65:4681–4690
     [Google Scholar]
  7. Cubie H. A., Norval M., Crawford L., Banks L., Crook T. 1989; Lymphoproliferative response to fusion proteins of human papillomavirus in patients with cervical intraepithelial neoplasia. Epidemiology and Infection 103:625–632
     [Google Scholar]
  8. Dillner J. 1990; Mapping of linear epitopes of human papillomavirus type 16: the El, E2, E4, E5, E6 and E7 open reading frames. International Journal of Cancer 46:703–711
     [Google Scholar]
  9. Ho G. Y. F., Burk R. D., Fleming I., Klein R. S. 1994; Risk for genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. International Journal of Cancer 56:788–792
     [Google Scholar]
  10. Jenison S. A., Yu X. P., Valentine J. M., Galloway D. A. 1991; Characterization of human antibody-reactive epitopes encoded by human papillomavirus types 16 and 18. Journal of Virology 65:1208–1218
     [Google Scholar]
  11. Jochmus-Kudielka I., Schneider A., Braun R., Kimmig R., Koldovsky U., Schnewies K. E., Seedorf K., Gissmann L. 1989; Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. Journal of the National Cancer Institute 81:1698–1703
     [Google Scholar]
  12. Kadish A. S., Hagan R., Ritter D. B., Goldberg G., Romney S. L., Kanetsky P. A., Beiss B. R., Burk R. D. 1992; Biologic characteristics of specific HPV types predicted from morphology of cervical lesions. Human Pathology 23:1262–1269
     [Google Scholar]
  13. Kiviat N., Rompalo A., Bowden R., Galloway D., Holmes K. K., Corey L., Roberts P. L., Stamm W. E. 1990; Anal human papillomavirus infection among human immunodeficiency virus-seropositive and -seronegative men. Journal of Infectious Diseases 162:358–361
     [Google Scholar]
  14. Koutsky L. A., Holmes K. K., Critchlow C. W., Stevens C. E., Paavonen J., Beckmann A. M., Derouen T. A., Galloway D. A., Vernon D., Kiviat N. B. 1992; A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. New England Journal of Medicine 327:1272–1278
     [Google Scholar]
  15. Krchnáňk V., Vágner J., Suchánková A., Krčmář M., Ritterová L., Vonka V. 1990; Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. Journal of General Virology 71:2719–2724
     [Google Scholar]
  16. Lorincz A. T., Reid R., Jenson A. B., Greenberg M. D., Lancaster W., Kurman R. J. 1992; Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstetrics and Gynecology 79:328–337
     [Google Scholar]
  17. Mclean C. S., Sterling J. S., Mowat J., Nash A. A., Stanley M. A. 1993; Delayed-type hypersensitivity response to the human papillomavirus type 16 E7 protein in a mouse model. Journal of General Virology 74:239–245
     [Google Scholar]
  18. Mandelson M. T., Jenison S. A., Sherman K. J., Valentine J. M., Mcknight B., Daling J. R., Galloway D. A. 1992; The association of human papillomavirus antibodies with cervical cancer risk. Cancer Epidemiology Biomarkers and Prevention 1:281–286
     [Google Scholar]
  19. Margalit H., Spouge J. L., Cornette J. L., Cease K. B., Delisi C., Berzofsky J. A. 1987; Prediction of immunodominant helper T cell antigenic sites from the primary sequence. Journal of Immunology 138:2213–2229
     [Google Scholar]
  20. Morrison E. A. B., Ho G. Y. F., Vermund S. H., Goldberg G. L., Kadish A. S., Kelley K. F., Burk R. D. 1991; Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study. International Journal of Cancer 49:6–13
     [Google Scholar]
  21. Müller M., Gausepohl H., De Martynoff G., Frank R., Brasseur R., Gissmann L. 1990; Identification of seroreactive regions of the human papillomavirus type 16 proteins E4, E6, E7 and LI. Journal of General Virology 71:2709–2717
     [Google Scholar]
  22. Müller M., Viscidi R. P., Sun Y., Guerrero E., Hill P. M., Shah F., Bosch F. X., Munoz N., Gissmann L., Shah K. 1992; Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer. Virology 187:508–514
     [Google Scholar]
  23. Myers E. W., Miller W. 1988; Optimal alignments in linear space. Computer Applications in the Biosciences 4:11–17
     [Google Scholar]
  24. Reeves W. C., Brinton L. A., Garcia M., Brenes M. M., Herrero R., Gaitan E., Tenorio F., Debritton R. C., Rawls W. E. 1989; Human papillomavirus infection and cervical cancer in Latin America. New England Journal of Medicine 320:1437–1441
     [Google Scholar]
  25. Rogozinski T. T., Jablowska S., Jazabek-Chorzelska M. 1988; Role of cell-mediated immunity in spontaneous regression of plane warts. International Journal of Dermatology 27:322–326
     [Google Scholar]
  26. Salgame P. R., Abrams J. S., Clayberger C., Goldstein H., Convit J., Modlin R. L., Bloom B. R. 1991; Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279–282
     [Google Scholar]
  27. Schneider A., Koutsky L. A. 1992; Natural history and epidemiological features of genital HPV infection. In The Epidemiology of Cervical Cancer and Human Papillomavirus pp 25–52 Munoz N., Bosch F. X., Shah K. V., Meheus A. Edited by Lyon: International Agency for Research on Cancer (WHO);
     [Google Scholar]
  28. Shepherd P. S., Tran T. T. T., Rowe A. J., Cridland J. C., Comerford S. A., Chapman M. G., Rayfield L. S. 1992; T cell responses to the human papillomavirus type 16 E7 protein in mice of different haplotypes. Journal of General Virology 73:1269–1274
     [Google Scholar]
  29. Stoler M. H., Rhodes C. R., Whitbeck A., Wolinsky S. M., Chow L. T., Broker T. R. 1992; Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Human Pathology 23:117–128
     [Google Scholar]
  30. Strang G., Hickling J. K., Mcindoe G. A. J., Howland K., Wilkinson D., Ikeda H., Rothbard J. B. 1990; Human T cell responses to human papillomavirus type 16 LI and E6 synthetic peptides: identification of T cell determinants, HLA-DR restriction and virus type specificity. Journal of General Virology 71:423–431
     [Google Scholar]
  31. Tindle R. W., Smith J. A., Geysen H. M., Selvey L. A., Frazer I. H. 1990; Identification of B epitopes in human papillomavirus type 16 E7 open reading frame protein. Journal of General Virology 71:1347–1354
     [Google Scholar]
  32. Tindle R. W., Fernando G. J. P., Sterling J. C., Frazer I. H. 1991; A ‘public’ T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proceedings of the National Academy of Sciences U.S.A: 885887–5891
     [Google Scholar]
  33. Vermund S. H., Kelley K. F., Klein R. S., Feingold A. R., Schreiber K., Munk G., Burk R. D. 1991; High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. American Journal of Obstetrics and Gynecology 165:392–400
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-75-9-2277
Loading
Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific
J. Gen. Virol. 75, 2277 (1994); https://doi.org/10.1099/0022-1317-75-9-2277
/content/journal/jgv/10.1099/0022-1317-75-9-2277
/content/journal/jgv/10.1099/0022-1317-75-9-2277
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error